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Genome-wide association of mood-incongruent
psychotic bipolar disorder
FS Goes1,8, ML Hamshere2,8, F Seifuddin1, M Pirooznia1, P Belmonte-Mahon1, R Breuer3, T Schulze4, M No¨then5, S Cichon5,
M Rietschel3, P Holmans2, PP Zandi6, Bipolar Genome Study (BiGS), N Craddock2,9 and JB Potash7,9
Mood-incongruent psychotic features (MICP) are familial symptoms of bipolar disorder (BP) that also occur in schizophrenia
(SZ), and may represent manifestations of shared etiology between the major psychoses. In this study we have analyzed three
large samples of BP with imputed genome-wide association data and have performed a meta-analysis of 2196 cases with MICP
and 8148 controls. We found several regions with suggestive evidence of association (Po10–6), although no marker met
genome-wide significance criteria. The top associations were on chromosomes: 6q14.2 within the PRSS35/SNAP91 gene
complex (rs1171113, P¼ 9.67 10–8); 3p22.2 downstream of TRANK/LBA1 (rs9834970, P¼ 9.71 10–8); and 14q24.2 in an intron
of NUMB (rs2333194, P¼ 7.03 10–7). These associations were present in all three samples, and both rs1171113 and rs2333194
were found to be overrepresented in an analysis of MICP cases compared with all other BP cases. To test the relationship of
MICP with SZ, we performed polygenic analysis using the Psychiatric GWAS Consortium SZ results and found evidence of
association between SZ polygenes and the presence of MICP in BP cases (meta-analysis P¼ 0.003). In summary, our analysis of
the MICP phenotype in BP has provided suggestive evidence for association of common variants in several genes expressed in
the nervous system. The results of our polygenic analysis provides support for a modest degree of genetic overlap between BP
with MICP and SZ, highlighting that phenotypic correlations across syndromes may be due to the influence of polygenic risk
factors.
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Introduction
Bipolar disorder (BP) is among the more reliably diagnosed1
and most heritable illnesses in psychiatry.2 Although a recent
large-scale genome-wide association study (GWAS) meta-
analysis found strong evidence for association of common
markers in the calcium channel subunit gene CACNAC1 and
the cell-surface protein gene ODZ4 with BP, the effect sizes
are modest and account for only a small proportion of the
phenotypic variance and heritability.3 Several hypotheses
have been proposed to explain why gene identification in
psychiatric phenotypes such as BP has met with less success
than might have been anticipated. Among these are a higher
burden of rare variants,4 a more polygenic genetic architec-
ture5 and a more heterogeneous phenotype.6
If the search for etiology is complicated by phenotypic
heterogeneity, a potential method to mitigate this problem
might be to delineate clinical subphenotypes that could be
more biologically homogenous. Such phenotypes may also
help uncover potential susceptibility risk factors for domains of
psychopathology that may be shared across diagnoses. In
this study, we focus on the Diagnostic and Statistical Manual
of Mental Disorders (DSM)-IV subtype of BP with mood-
incongruent psychotic features (MICP). This subphenotype
was first described a century ago as a potential diagnostic tool
to differentiate the more common mood-congruent psychotic
symptoms of mood disorders from the mood-incongruent
psychotic symptoms of SZ.7 More modern conceptions of BP
no longer exclude cases with mood-incongruent psychotic
symptoms, which are now believed to comprise one-third to
one-half of all psychotic BP.8,9 Mood-incongruent psychotic
symptoms in BP appear to be important markers of severity,
being associated with worse overall outcome,10,11 poor lithium
responsiveness12 and higher rates of attempted suicide.8,9
The presence of MICP symptoms might also be a
manifestation of overlapping genetic susceptibility between
BP and SZ. Family studies have found a modestly elevated
risk of SZ in relatives of cases with mood disorders and
MICP,13,14 and vice versa.15 More recently, two genome-wide
linkage scans of BP with MICP have been performed;9,16
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while there was limited overlap between the two, a number of
genome-wide suggestive signals emerged in regions pre-
viously implicated in SZ linkage studies, including on
chromosomes 1p32, 2q12 and 13q31.
We hypothesize that the BP subtype with MICP features
may help uncover susceptibility genes for BP not readily
detectable by examining the broad BP phenotype. Given
the clinical similarities between MICP symptoms in BP and
in SZ, we also hypothesize that some of these susceptibility
genes would show partial overlap with susceptibility genes
for SZ. To test these hypotheses, we have performed a
GWAS analyses of the MICP phenotype using several large
BP data sets and further sought to determine whether our
findings might also influence susceptibility to SZ, by making
use of the recently published Psychiatric GWAS Consortium
(PGC) SZ results.
Materials and methods
Subjects. Subjects with BP and MICP were initially drawn
from three large, independent samples of BP, here termed
the National Institute of Mental Health Bipolar Disorder
Consortium (NIMH), the Wellcome Trust Case–Control
Consortium (WTCCC) and the German samples. Subject
collection and genotyping were conducted separately for
each sample. However, quality control steps taken in the
analyses of these samples have been identical.
NIMH sample. Eligibility, ascertainment and assessment
procedures for the NIMH sample have been previously
described.17 All subjects were assessed with the Diagnostic
Interview for Genetic Studies (DIGS), and this was combined
with family informant data and medical records to assign
diagnoses based on DSM-III-R or DSM-IV criteria. Controls
were ascertained throughout the United States and were
genotyped as part of the Molecular Genetics of Schizo-
phrenia II (MGS2) Collaboration.18 All control subjects
completed a psychiatric questionnaire and those endorsing
a history of BP, psychosis or symptoms sufficient for a
diagnosis of major depression were excluded. Controls were
matched to cases according to ethnicity and sex.
Wellcome Trust Case–Control Consortium. The WTCCC
sample comprised the original 1868 participants with BP and
2938 controls from the WTCCC-1 study, and an additional
2725-independent controls from the WTCCC-2 study. Clin-
ical assessment included a semi-structured interview and
review of case notes. Ratings of symptom occurrence and
course of illness were made using the Bipolar Affective
Disorder Dimension Scale19 and/or the operational criteria
(OPCRIT) item check list.20 Diagnoses were based on all
available data using the Research Diagnostic Criteria.21 Both
WTCCC-1 and WTCCC-2 controls were evenly ascertained
from the 1958 British Birth Cohort and the UK Blood Service
Control Group samples.
German sample. The collection and genotyping of the
German BP sample has been recently described.22 In brief,
probands with bipolar I disorder were recruited through
consecutive hospital admissions and assessed using a
structured interview and the OPCRIT checklist. Best-
estimate diagnoses were assigned according to DSM-IV
criteria. A population-based control sample screened for
psychiatric disorders was assembled from the PopGen,
KORA and Heinz Nixdorf Recall studies.
Mood-incongruent psychosis phenotype. Considerable
attention was given to ensuring comparability between the
phenotypes across the three samples. While the NIMH,
WTCCC and German samples used different diagnostic
instruments (that is, DIGS, Bipolar Affective Disorder
Dimension Scale, OPCRIT) to diagnose participants, the
psychotic symptoms queried by these interviews are quite
similar and, in many cases, identical. In all studies, mood-
incongruence was defined according to the DSM-IV definition
as psychotic ‘contentyinconsistent with depressive themes
such as guilt, illness, personal inadequacy or catastrophe...
[or] inconsistent with manic themes such as inflated worth,
power, knowledge, identity, or special relationship to a deity
or famous person.’ Further DSM-IV mood-incongruent
psychotic symptoms include ‘delusions of thought insertion
yof thought broadcasting, andyof control’.
For the NIMH samples, the designation of psychotic
features was based on a lifetime history of auditory or visual
hallucinations or delusions. In the DIGS subjects are asked
about the presence of psychotic symptoms during their most
severe depression, as well as during a subsequent review of
lifetime psychotic symptoms. Interviewers were asked to
determine the incongruence of psychotic content following
descriptions of hallucinations or delusions in a mood episode.
At least one positive response to these questions in either
depressive or manic episodes rendered a subject positive for
a lifetime history of mood-incongruence. If insufficient
information was available to rule in or rule out a lifetime
presence of mood-incongruent psychosis, the case was
designated as indeterminate. In the genotyped NIMH sample
of 2191 BP cases, 1372 (62.6%) were classified as having a
lifetime history of psychosis and 960 (43.8%) met criteria for a
lifetime history of mood-incongruent psychosis.
The WTCCC study used a semi-structured diagnostic
instrument similar to the DIGS, which was then used to
complete the Bipolar Affective Disorder Dimension Scale and
OPCRIT rating scales. The designation of mood-incongru-
ence was made if a case had a rating of 420 in the Bipolar
Affective Disorder Dimension Scale mood-incongruent dimen-
sion or if the OPCRIT ratings (questions 54, 58, 59, 61–63,
66–68, 72–77) were positive for any of the DSM-IV mood-
incongruent items. Out of the 1868 cases from the WTCCC-1
study, 873 (46.7%) were classified as having had MICP.
In the German study, the designation of mood-incongru-
ence was made using the OPCRIT items that reflected the
DSM-IV definition. Of the 645 cases with BPI, 363 (56.3%)
were classified as having had mood-incongruent psychosis.
Genotyping
National Institute of Mental Health Bipolar Disorder Con-
sortium. Unrelated cases and controls were genotyped in
two separate stages by the Bipolar Genome Study. In all,
1001 cases and 1034 controls selected for the Genetic
Association Information Network study were genotyped by
Mood-incongruent psychotic bipolar disorder
FS Goes et al
2
Translational Psychiatry
the Broad Institute using the Affymetrix 6.0 platform (Santa
Clara, CA, USA), while an additional 1190 cases and 401
controls were genotyped by the Translational Genomics
Research Institute, also on the Affymetrix 6.0 platform. We
included the final cleaned data set from the primary case–
control analysis of each sample. The Genetic Association
Information Network-BP sample included genotype data on
724067 single-nucleotide polymorphisms (SNPs). The
Translational Genomics Research Institute data set included
genotype data on 728 187 SNPs.
Wellcome Trust Case–Control Consortium. Genotyping was
conducted in two stages, with cases and controls available
from WTCCC-1 and controls only from WTCCC-2. The
combined WTCCC-1 and 2 samples consisted of 1868 cases
and 5682 controls (2957 from WTCCC-1 and 2725 from
WTCCC-2). There were 382 370 SNPs generated using
Affymetrix 5.0 from stage 1 and 696 889 SNPs generated
from the Affymetrix 6.0 platform in stage 2.
German sample. The genotyping of the German BP sample
has been recently described.22 Genotyping was performed
on the Illumina HumanHap550 array (Illumina Inc, San
Diego, CA, USA). We utilized the final cleaned data set,
which included 645 cases and 1310 controls with genotype
data on 516024 SNPs.
Data management
Quality control. Each data set underwent identical quality
control steps. We dropped subjects with a missing data
rateX3%, and SNPs with a missing data rateX5%. SNPs
were also dropped if their frequency waso1% or if they had a
Hardy–Weinberg equilibrium Po0.001. The quality control
steps were applied to each study individually before and after
imputation, as well as to the combined mega-analysis
sample. To assess for cryptic relatedness, genotyped SNPs
for each study were combined and identity by descent
analysis was performed using a linkage disequilibrium-
pruned data set. We removed one of any pair of individuals
with identity by descent score sharing40.2.
Principal component analysis. To account for population
stratification in the GWAS sample, we performed principal
component analysis within each data set using markers in
linkage equilibrium (R2o0.2) with a minor allele frequency
45%. We also excluded all AT/GC SNPs and all SNPs within
the major histocompatibility complex (chr6: 25–23Mb) and
chromosome 8 inversion (chr8: 7–13Mb) regions.
Principal components were selected based on visualization
of a screen plot (graphs of the principal components are
shown in Supplementary Figure 1). Plotting of the principal
components showed two, 11, and one clear outlier(s) in the
NIMH,WTCCCandGerman data sets, respectively, that were
removed.
Imputation. Imputation was performed to facilitate a meta-
analysis of the three data sets, which were originally
genotyped on Affymetrix 5.0 (WTCCC-1), Affymetrix 6.0 (all
NIMH and the WTCCC-2 control samples) and Illumina
HumanHap550v3 microarray chips. We used BEAGLE to flip
orientation to the positive strand and to impute allelic
dosages for autosomal SNPs in the cases and controls.
Each data set was imputed separately using phased
haplotype data from HapMap I & II release 24 (http://
hapmap.ncbi.nlm.nih.gov/) as the reference panel. The
WTCCC, NIMH, and German samples were imputed
separately and subsequently combined. Quality control filters
were applied to the individual studies and to the combined
data set. SNPs were removed according to the following
criteria: minor allele frequencyo0.01, R2o0.3, Hardy-Wein-
berg equilibrium Po0.001 and a PLINK INFO scoreo0.8.
The final imputed files contained 2 488722 (NIMH),
2 404 996 (WTCCC) and 2 472086 (German) markers.
Data analysis
Association analysis. We used the imputed allelic data
from the NIMH, WTCCC and German data sets and
performed test of association in logistic regression analysis
for each dataset, comparing cases with MICP versus
controls. Tests of association were performed in PLINK
using allelic dosages in an additive logistic regression model
including covariates for the top principal components. As a
measure of potential residual population stratification, we
used WGAviewer (Duke University, Durham, NC, USA) to
calculate lambda (l) as the ratio of the median observed
versus expected w2 statistic. To facilitate comparison with
other samples, we also calculated a standardized lambda
(l1000) for a sample of 1000 cases and 1000 controls.
Case-only analysis. We performed a case-only analysis of
our top findings. Principal components and association
studies were performed in each individual sample using all
cases with MICP versus all other cases without MICP. As
several variables can lead to the designation of MICP, we
included as negative only those subjects without any missing
data for those variables.
Meta-analysis. Association analysis of each data set was
performed with data set-specific principal components. Meta-
analysis was subsequently performed in PLINK under a fixed
effect model for both the case–control and case-only
analysis.
Polygenic analysis. Using the PGC SZ results as a training
set, we performed a polygenic analysis of each of the three
samples in cases with and without MICP. The PGC SZ
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Figure 1 Manhattan plot of the meta-analysis comparing cases with bipolar
disorder with mood-incongruent psychotic features to normal controls.
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results were clumped into a data set of 85 284 markers in
linkage equilibrium (r2o0.25) using the CEU HapMapII
samples as a reference. We used PLINK to calculate
polygenic scores using the SZ risk alleles weighted by their
log(OR) as the initial training set sample. Polygenic scores
were derived in each individual MICP samples using several
Table 1 Meta-analysis results for the comparison of bipolar disorder cases with mood-incongruent psychotic features to normal controls, showing markers
associated with a Po1 10–5
Chromosome Location (bp) Marker Relation to
gene
Distance to
gene (bp)
Gene Risk
allele
Odds
ratio
P(meta)
6 84283314 rs1171113 Intronic 0 PRSS35/SNAP91 C 1.23 9.67 10 8
3 36831034 rs9834970 Upstream 12278 TRANK1/LBA T 0.82 9.71 10 8
14 72836967 rs2333194 Intronic 0 NUMB A 0.83 7.03 10 7
3 5680052 rs11710433 Intergenic N/A C 0.81 1.16 10 6
3 13712001 rs4450798 Intergenic 57078 FBLN2 T 1.26 1.54 10 6
8 54717753 rs11773966 Intronic 0 ATP6V1H A 2.17 1.92 10 6
3 52693320 rs10865974 Intronic 0 PBRM1/GNL3 T 0.84 2.18 10 6
17 6034675 rs3744728 Intergenic 66204 WSC domain containing 1 C 1.51 2.80 10 6
1 30298301 rs2860031 Intergenic N/A G 0.82 2.81 10 6
1 24304543 rs3934861 Intronic 0 MYOM3 A 0.8 3.76 10 6
7 137509306 rs10255295 Intergenic 55716 AKR1D1 G 1.31 4.73 10 6
10 32349011 rs1775715 Intronic 0 KIF5B G 1.18 5.13 10 6
5 17268444 rs2962370 Upstream 2306 BASP1 G 1.19 5.14 10 6
6 37282723 rs1680005 Upstream 5209 TMEM217 A 1.18 7.45 10 6
2 98450324 rs12617721 Intronic 0 INPP4A C 1.2 7.45 10 6
22 24205265 rs1930961 Intergenic 17620 CRYBB2P1 C 0.72 9.49 10 6
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Figure 2 Regional and forest plots of the top three findings in the case–control meta-analysis. Results are shown for: (a) PRSS35/SNAP91, (b) TRANK1/LBA1 and
(c) NUMB. Genome coordinates are based on NCBI 36/hg 18 build and recombination rates are derived from the HapMapII CEU sample.
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P-value thresholds. A case-only logistic regression was
subsequently performed for each data set using the
polygenic scores as the dependent variable and each study’s
principal components as covariates. Fixed effect meta-
analysis of each association was subsequently performed
in STATA (Stata Corp, College Station, TX, USA) using its
‘meta’ function. As a majority of the controls in the MICP
analysis (5022 out of 8148) overlapped with the controls in
the PGC schizophrenia (SZ) analysis, we restricted our MICP
analysis to a case-only analysis.
Results
We first performed association analyses of each individual
data set. The number of cases with mood-incongruent
psychosis across the three data sets was 960 (43.8%) in the
NIMH, 873 (46.7%) in the WTCCC and 363 (56.3%) in the
German samples. Quantile-quantile (QQ) plots for each
sample are shown in Supplementary Figure 1. The l
estimates were 1.01, 1.04 and 1.02 for the NIMH, WTCCC
and German samples, respectively. There were no genome-
wide significant findings within each sample, leading us to
proceed to a fixed effect meta-analysis of the three data sets.
The meta-analysis included a total of 2196 cases with BP with
MICP and 8418 controls.
As shown in Figure 1 and Table 1, the most highly
associated marker in the meta-analysis was rs1171113, with
the C allele being overrepresented in cases (odds ratio
(OR)¼ 1.23, P¼ 9.67 10–8). Figure 2a highlights this
association in more detail, showing that rs1171113 tags an
B150–200 kb region of chromosome 6q14.2 that encom-
passes the genesPRSS35 (protease, serine 35) andSNAP91
(synaptosomal-associated protein, 91 kDa homolog, also
known as clathrin coat assembly protein AP180). The second
strongest association was found on chromosome 3p22.2
with the rs9834970 marker (risk allele¼T; OR¼ 0.82;
P¼ 9.71 10–8). As shown in Figure 2b, this marker is
B15 kb downstream of TRANK1 (tetratricopeptide repeat
and ankyrin repeat containing 1 gene), also known as LBA1
(lupus brain antigen 1). Finally, Figure 2c shows the third
strongest finding with a Po10 6, on chromosome 14q24.2
(rs2333194; P¼ 7.0  10–7), which is in the third intron of
NUMB. To determine whether these top findings were
specifically associated with MICP, we performed a logistic
regression analysis comparing BP cases with MICP versus all
other BP cases. We found evidence of association of the risk
alleles with MICP cases in two of our top findings: rs1171113
(OR¼ 1.14, P¼ 0.014) and rs2333194 (OR¼ 1.12, P¼ 0.02),
but not in rs9834970 (OR¼ 1.04, P¼ 0.42).
To test the hypothesis that the MICP subset of BP may be
associated with SZ, we performed a polygenic analysis of the
MICP data set using a case-only design, as most of the
controls in this study overlap with those of the PGC SZ study.
First, we selected commonmarkers between the PGCSZ and
our MICP data sets and subsequently performed linkage
disequilibrium-pruning to obtain markers in approximate
linkage disequilibrium (r2o0.25). We derived a polygenic
score from the PGC SZ analysis using several association P-
value thresholds, ranging from 0.05–0.5, and performed a
logistic regression analysis in each case-only sample, testing
whether an individual’s polygenic score was associated with
the presence or absence of MICP. Each sample was
corrected for by its study-specific principal components. In a
meta-analysis of the three samples, we found significant
evidence for polygenic overrepresentation of SZ risk alleles in
BP cases with MICP (Table 2), with the strongest evidence of
association found at the Po0.2 threshold (Pmeta¼ 0.003).
Evidence of association was found across all P-value thresh-
olds, suggesting that this association was unlikely to be
spurious.
Discussion
In this study we have combined three large BP GWAS
samples to test the hypotheses that (1) a subphenotype of BP,
marked by MICP, would show association in loci not found in
analyses of the more broadly defined phenotype; and (2) that
the MICP BP subphenotype would show evidence at a
broader level for a relationship with SZ. Our meta-analysis
of 2196 cases and 8418 controls found association of several
markers with Po1 10–6, though none reached genome-
wide significance. Prior family studies suggested that mood
disorders with MICP might be etiologically related to SZ.14,23
In support of this hypothesis, our polygenic analysis using risk
alleles from the PGC SZ GWAS study found an association,
en masse, between large numbers of SZ variants and the
presence of MICP in BP cases, suggesting that genetic
overlap across syndromes is potentially due to shared
polygenic variation with individual effects that are likely too
small to be detected in single marker GWAS analyses.
The marker with the strongest association (rs1171113),
which was enriched in the case-only analysis, resides in a
region of high linkage disequilibrium that includes the genes
PRSS35 and SNAP91. The PRSS35 gene encodes an
inactive serine protease homolog of no known function
(reference uniprot database24). SNAP91 codes for a 91 kDa
synaptosomal-associated protein, also known as clathrin
assembly protein 180 (AP180), which is enriched in the
presynaptic terminal and expressed only in neurons.25
SNAP91 is essential for the formation and function of clathrin
coated vesicles, which are the major means of recycling
vesicles at the presynaptic membrane.26 Interestingly,
SNAP91 has also been proposed to have a role in calcium
signaling and the Wnt pathway. Studies have found that the
SNAP91 protein can inhibit two important intracellular signal-
ing molecules, phospholipase C-g1 and phospholipase
Table 2 Association of PGC schizophrenia polygenic scores with mood-
incongruent psychosis in cases with bipolar disorder
Threshold P-value
(PGC schizophrenia
training data set)
Regression
Z-statistic
MICP case-only
P-value
Po0.05 2.59 0.01
Po0.1 2.59 0.01
Po0.2 3.00 0.003
Po0.3 2.91 0.004
Po0.4 2.86 0.004
Po0.5 2.76 0.006
Abbreviations: MICP, mood-incongruent psychotic features; PGC, Psychiatric
GWAS Consortium.
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D1.27,28 Both molecules have been implicated in the Wnt
pathway29 and phospholipase C-g1 has a pivotal role in
intracellular inositol signaling, which is hypothesized to have a
role in lithium’s mechanism of action. As some studies have
suggested that BP with mood-incongruent psychosis is less
responsive to lithium treatment,12,30 it is intriguing to spec-
ulate that SNAP91, via its effect on phospholipase C-g1, may
be involved in lithium response.
Our second strongest association signal (rs9834970) is
E12 kb downstream of the LBA1 gene, which is also known
as TRANK1 (tetratricopeptide repeat and ankyrin repeat
containing 1), and was originally identified as a brain-specific
antigen in a murine model of systemic lupus erythematosus, a
human disorder with frequent neuropsychiatric symptoms.31
This marker was recently found to have genome-wide
significant evidence for association with BP in a large meta-
analysis of mixed ancestry samples.32 Notably, this marker
also showed suggestive evidence for association with SZ in
the PGCSZmeta-analysis (p¼ 3.6 10–5).33 Our association
with this marker was found with far smaller sample sizes;
however, we did not find evidence that the rs9834970 risk
allele was specifically associated with MICP in a case-only
analysis, suggesting that this marker is likely to be represen-
tative of a risk allele for the broader diagnosis of BP. Our third
strongest association (rs2333194) did show modest over-
representation in MICP in our case-only analysis and was
found in NUMB, an important modulator of the notch signaling
pathway, which among other functions, has been shown to
regulate neuronal differentiation in vitro.34
Psychiatric phenotypes are likely amalgams of multiple
genetic, development and environmental influences.
Although single gene findings can illuminate important
pathophysiological mechanisms, phenotypic considerations
are likely to be more correlated with markers of aggregate
genetic effects, such as familiality or ‘global’ genetic analysis
like polygenic risk profiling.35 In this study such a polygenic
analysis has found evidence for association of the MICP BP
phenotype with SZ, which is consistent with prior family
studies, and provides further support for etiological ties
between the major mood and psychotic disorders. A prior
study found a similar association between SZ and a
phenotype that is closely related to BP with MICP, that of
schizoaffective disorder as diagnosed by the Research
Diagnostic Criteria.36 Although cases with RDC schizoaffec-
tive disorder are included within our diagnosis of BP with
MICP, we were not able to derive this RDC-based diagnosis
from the DSM-based DIGS interview.
The results of this study should be interpreted in light of
several limitations. Perhaps most important is the limited
power to detect risk variants of small effect sizes, particularly
as loss of statistical power is inherent in the subphenotype
approach, which splits a broader case sample into smaller
units. Even with the three large BP samples, our study
(assuming a common and fully informative marker allele) only
had sufficient power to detect ORs in theE1.3 range, which is
slightly greater than that of our top finding (OR¼ 1.23).
Although larger samples will provide increased statistical
power, they will also create the challenge that arises from the
need to harmonize subphenotype definitions. As patients with
psychosis may fail to recall specific psychotic symptoms,37
differential misclassification of mood-incongruence is an
important concern, particularly in case-only analysis, which
prompted us to focus our primary analysis on a case–control
design.
In summary, we have performed a large GWAS of theMICP
subphenotype and found no associations meeting genome-
wide significance criteria, although several associations at the
‘suggestive’ level warrant further investigation. More globally,
our polygenic analysis has found modest evidence for
association of the MICP BP phenotype with SZ, which is
consistent with prior family studies, and provides further
support for etiological ties between the major mood and
psychotic disorders.
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